SQ109 is primarily investigated for its potential as an anti-tuberculosis agent. It shows promise in treating drug-resistant strains of Mycobacterium tuberculosis, often in combination with existing therapies. Beyond tuberculosis, SQ109 is being explored for its antimicrobial properties against other bacterial infections, including those caused by Gram-positive and Gram-negative bacteria. Additionally, it has shown potential in cancer research, where it may inhibit cancer cell growth by targeting specific cellular pathways. Its ability to modulate immune responses is also under study, suggesting possible applications in autoimmune diseases and inflammatory conditions.